Introduction {#Sec1}
============

Schnyder corneal dystrophy (SCD; OMIM \#121800) is a rare autosomal dominant disease classified within the group of stromal dystrophies (IC3D 2015, \[[@CR1]\]) and caused by *UBIAD1* pathogenic variants \[[@CR2]--[@CR4]\]. SCD is characterized by progressive opacification of both corneas resulting from excessive cellular and intracellular accumulation of cholesterol and phospholipids in the corneal stroma. Lipid deposits may take form of crystals, non-crystalline stromal opacity, or *arcus lipoides* \[[@CR2]\]. Chemical analysis of SCD corneas shows a tenfold higher content of cholesterol and fivefold higher content of lipids compared to healthy corneas \[[@CR5]\]. SCD prevalence in the general population remains unknown. Early stages of the disease may be asymptomatic and the diagnosis may be delayed until the occurrence of a distinct haze or crystals, commonly in the second decade of life \[[@CR6]\]. While SCD scotopic vision usually remains preserved until the late stages of the disease, photopic vision deteriorates more rapidly with the progression of corneal opacification \[[@CR5], [@CR7]\]. Patients complain of decreasing visual acuity (VA) and glare which is caused by light scattering from the surfaces of corneal crystals. In order to recover vision quality in advanced stages of SCD, penetrating keratoplasty (PKP) is performed. In a group of 115 individuals from 34 SCD families, 54% of patients of at least 50 years and 77% of patients aged 70 or over were subjected to PKP \[[@CR5]\].

To date, 27 non-synonymous point alterations of the *UBIAD1* gene causative of SCD have been described \[[@CR8]--[@CR11]\]. The most frequent pathogenic variants include p.Asn102Ser, p.Gly177Glu/Arg, and p.Leu121Phe. In 2016, p.Thr103Ile, the first de novo *UBIAD1* gene pathogenic variant associated with SCD was identified \[[@CR9]\]. UBIAD1 protein is predicted to contain ten transmembrane (TM) helices, nine of which lie within a functional prenyltransferase domain \[[@CR12]\], which is a key part of the UBIAD1 protein enzymatic activity \[[@CR10], [@CR12]--[@CR14]\]. TM helices emerge from the lipid bilayer into three soluble polypeptide loops. All of the so far identified pathogenic variants leading to SCD encompass this domain \[[@CR10]\]. The first loop is most frequently affected by SCD pathogenic variants which appear to disturb its hydrophilic property \[[@CR14]\].

The purpose of the study was to report two known and a novel *UBIAD1* gene variant causative of SCD and present a clinical and molecular characterization of the disease in the context of systemic findings in four previously unreported Polish SCD families.

Patients and methods {#Sec2}
====================

Study subjects {#Sec3}
--------------

Blood samples were collected from 37 individuals (14 SCD affected, 21 unaffected, and 2 not examined ophthalmologically) from four Polish families (Ped. nos. 690, 411, 149, 272, Fig. [1](#Fig1){ref-type="fig"}a--d), one of them with a three-generation history of SCD (Ped. no. 272, Fig. [1](#Fig1){ref-type="fig"}d).Fig. 1Pedigrees of the analyzed SCD familiesFor every examined patient a corresponding identification number (\#PatID format) together with a detected *UBIAD1* allelic variant (wt-- wild type, p.Thr120Arg -- Pedigree no. 690 (**a**), p.Asp112Asn -- Pedigree no. 411 (**b**), p.Asn102Ser -- Pedigree nos. 149 and 272 (**c** and **d**)) are shown. Black symbols indicate affected, white symbols unaffected individuals, symbols with a diagonal line indicate deceased individuals, symbols with question mark indicate individuals not examined ophthalmologically, probands are marked with arrows

Ophthalmological evaluation {#Sec4}
---------------------------

The subjects underwent complete ophthalmological examinations including uncorrected and best corrected visual acuity (UCVA/BCVA), intraocular pressure measurement, and slit-lamp biomicroscopy. In patients with identified corneal changes, Anterior Segment-OCT (CASIA SS-1000, Tomey, Nagoya, Japan) and in vivo confocal microscopy (CS3/CS4, Nidek Tech., Padova, Italy) were also performed.

Genetic testing and bioinformatic analysis {#Sec5}
------------------------------------------

Genomic DNA was isolated from blood samples (*n* = 37) with a standard salting-out procedure. DNA pathogenic variant testing was performed by PCR amplifying and Sanger sequencing of the *UBIAD1* gene coding regions (exons 1 and 2). The PCR primer sequences designed using the reference sequence NG_009443.1 and amplification conditions are available upon request. DNA samples were purified with exonuclease I and FastAP thermosensitive alkaline phosphatase (Thermo Fisher Scientific, Waltham, Massachusetts, USA) according to the manufacturer's protocol, sequenced directly using ABI Prism 377 DNA Sequencer (Thermo Fisher Scientific) and BigDye Terminator v1.1 Cycle Sequencing Kit (Thermo Fisher Scientific) and analyzed with the Variant Reporter DNA analysis software v1.1 (Thermo Fisher Scientific).

Pathogenicity of the novel non-synonymous single nucleotide *UBIAD1* variant was predicted using PredictSNP2 \[[@CR15]\], FATHMM \[[@CR16]\], and MutPred2 \[[@CR17]\], leading and reliable computational approaches \[[@CR18]\] and analyzed for population frequency based on the data from Exome Aggregation Consortium (ExAC, <http://exac.broadinstitute.org>), 1000 Genomes Project (<http://www.1000genomes.org>), and NHLBI GO Exome Sequencing Project (ESP, <http://evs.gs.washington.edu/EVS>; all accessed 06/2018).

Results {#Sec6}
=======

Identified *UBIAD1* gene pathogenic variants in patients with SCD {#Sec7}
-----------------------------------------------------------------

*UBIAD1* gene pathogenic variants were found in a total of 18 subjects (11 females and 7 males aged 13--68 years; mean age 37.8 y/o). Two of them (III.7 PatID\#506 and III.6 PatID\#507) did not present signs of SCD, most probably because of their relatively young age (16 and 21 y/o, respectively) or incomplete penetrance of the identified *UBIAD1* variant. In the other two individuals (III.15 PatID\#459 and III.17 PatID\#511) with severe intellectual disability, a detailed ophthalmological examination could not be conducted (Table [1](#Tab1){ref-type="table"}). The remaining 19 unaffected subjects did not carry any *UBIAD1* disease-causing alteration (Fig. [1](#Fig1){ref-type="fig"}a--d).Table 1Clinical and genetic characterization of SCD patients from this studyPed. no.PedID/PatIDUBIAD1 pathogenic variantSexAge at examinationCrystals C/PHaze C/DArcus lipoidesBCVA OD/OSOther medical conditions690I.2/922p.Thr120ArgF44+ P−/−--0.7/0.5Hypertension, varicose veins51++++ C/P++0.2/0.2II.2/924p.Thr120ArgM22+ P−/−--1.0/0.9--II.3/925p.Thr120ArgM13+ P−/−--0.7/0.4intellectual disability, inguinal hernia411II.2/580p.Asp112AsnF65++++ C/P++0.8/0.7n/aII.3/644p.Asp112AsnF68++++ C/P+/++0.4/0.2↑ cholesterol, hypertension, cholelithiasisIII.1/579p.Asp112AsnF36++ C/P----0.9/0.9--149I.2/492p.Asn102SerF51n/an/an/an/an/aII.1/207p.Asn102SerM33++ C+/−--0.4/0.5--272II.1/379p.Asn102SerM47+++ C/P+/−+0.4/0.9↑ cholesterol, hypertensionII.3/486p.Asn102SerF49+ C/P−/−--0.8/0.5hypoacusisII.5/378p.Asn102SerF54++++ C/P+/−+0.4/0.5↑ cholesterol, hypertensionII.6/375p.Asn102SerF54++++ C/P+/−+0.4/0.3↑ cholesterolIII.6/507p.Asn102SerM21------n/aintellectual disabilityIII.7/506p.Asn102SerF16------n/a--III.15/459p.Asn102SerF29n/an/a--n/a↑ cholesterol, cholelithiasis, intellectual disabilityIII.16/460p.Asn102SerF31++ C/P−/−--0.8/0.8↑ cholesterolIII.17/511p.Asn102SerM26n/an/a--n/aintellectual disabilityIII.19/462p.Asn102SerM26+ P−/−--0.4/0.9--*Crystals C/P* central/paracentral, *haze C/D* central/diffused, *sex F/M* female/male, *n/a* not available

All pathogenic variants identified in the patients with SCD are located within the first exon of the *UBIAD1* gene. Genetic testing of the first family (Ped. no. 690) shown in Fig. [1](#Fig1){ref-type="fig"}a revealed a novel heterozygous missense variant NM_013319.2:c.359C\>G predicted to result in amino acid substitution NP_037451.1:p.Thr120Arg (Fig. [2](#Fig2){ref-type="fig"}f). The alteration completely segregated with the disease in the family and was predicted to be damaging by PredictSNP2 (score 1.0000, threshold range \<0; 1\> for pathogenic variants), FATHMM (score 0.8970, threshold range \<0.7; 1\> for pathogenic variants) and MutPred2 (score 0.8810, threshold range \<0.5; 1\> for pathogenic variants). The NM_013319.2:c.359C\>G transversion has not been reported in population databases.Fig. 2Corneal photographs and electropherograms of the corresponding *UBIAD1* pathogenic variants. First two columns contain slit-lamp photographs showing crystalline formations (**a**, **b**, **g**, **h**, **m**, **n**) in the central and paracentral cornea, arcus lipoides (**a**, **g**, **n**), and haze (**a**, **g**, **n**). Columns three and four contain IVCM images presenting spindle-shaped corneal deposits (**c**, **i**, **o**, **p**), homogeneous conglomerate of deposits (**d**), and microcysts at the epithelial level (**j**). The last column includes AS-OCT images with sagittal sections demonstrating hyperreflective opacities in the anterior part of the corneal stroma (**e**, **k**, **r**). Electropherograms from Sanger sequencing of *UBIAD1* exon 1 showing the identified c.359C \> G (p.Thr120Arg) (**f**), c.334G \> A (p.Asp112Asn) (**l**), and c.305A \> G (p.Asn102Ser) (**s**) pathogenic variants

In patients from the second family (Ped. no. 411), a heterozygous pathogenic variant NM_013319.2:c.334G\>A causing a missense change NP_037451.1:p.Asp112Asn was identified (Figs. [1](#Fig1){ref-type="fig"}b and [2](#Fig2){ref-type="fig"}l). Testing of patients from the third and fourth family (Ped. nos. 149 and 272, Fig. [1](#Fig1){ref-type="fig"}c, d) showed the presence of a heterozygous NM_013319.2:c.305A\>G pathogenic variant causing the NP_037451.1:p.Asn102Ser amino acid substitution (Fig. [2](#Fig2){ref-type="fig"}s) \[[@CR4], [@CR14]\].

Corneal changes in SCD patients from the investigated families {#Sec8}
--------------------------------------------------------------

Corneal thickness in all patients was within a normal range, and no signs of corneal edema were observed. All of the symptomatic individuals had corneal crystals.

In family with the novel p.Thr120Arg pathogenic variant (Ped. no. 690), the signs of asymptomatic SCD were identified as early as in the 6 year of age (II.3 PatID\#925, Fig. [1](#Fig1){ref-type="fig"}a) with the first symptoms occurring at the end of the fourth decade of life (37 y/o; I.2 PatID\#922, Fig. [1](#Fig1){ref-type="fig"}a). Dystrophic changes were located in the paracentral part of corneal stroma and took form of single crystals. They were more numerous in the proband (44 y/o) than in her two sons (22 and 13 y/o) and the phenotype was assessed as relatively mild. At this time of ophthalmological examination, there was no haze or arcus lipoides in the corneas of the affected individuals (Fig. [2](#Fig2){ref-type="fig"}b). AS-OCT images in the affected family members showed dystrophic changes in the form of highly reflective lines of deposits in the anterior and mid-stroma in the central and peripheral part of the cornea (Fig. [2](#Fig2){ref-type="fig"}e). IVCM examination in these subjects showed hyperreflective spindle-shaped deposits within the anterior and partly mid-stroma. They were thicker than those observed in patients with p.Asp112Asn and p.Asn102Ser pathogenic variants. Some images revealed diffuse homogenous structures without the spindle-shaped deposits (Fig. [2](#Fig2){ref-type="fig"}c, d). During the last 3-year observation period (48--51 y/o) corneal changes in the proband have progressed dramatically from single paracentral crystals to an advanced stage of SCD with arcus lipoides, stromal haze, central corneal opacity, and crystal conglomerates (Fig. [2](#Fig2){ref-type="fig"}a). Her BCVA progressed from 0.4 to 0.2. At the age of 51, she has been scheduled for a corneal surgery.

At the time of ophthalmological examination, the proband from family with the *UBIAD1* p.Asp112Asn variant (Ped. no. 411) was 28 y/o and did not present any symptoms of SCD. In her mother, the first symptoms occurred around the age of 60 years. Slit-lamp examination in the affected individuals from this family revealed age-dependent signs of SCD (Fig. [2](#Fig2){ref-type="fig"}g, h) \[[@CR5]\]. AS-OCT imaging showed hyperreflective deposits penetrating to the deep anterior and middle parts of the stromal layer in the central cornea. At the epithelial side, the upper border of the deposits was slightly irregular (Fig. [2](#Fig2){ref-type="fig"}k). IVCM examination revealed the presence of thin, hyperreflective spindle-shaped deposits (Fig. [2](#Fig2){ref-type="fig"}i). Some of them conglomerated into characteristic homogeneous substance comparable to dystrophic changes observed in IVCM images of Reis-Bücklers and Thiel-Behnke corneal dystrophy \[[@CR1]\]. Additionally, in the basal epithelial layer, single microcysts were found and they were similar to those observed in Meesmann's corneal dystrophy (Fig. [2](#Fig2){ref-type="fig"}j) \[[@CR19]\]. At the age of 68, the proband's mother underwent PKP due to a low VA as a consequence of SCD progression. After 4 years post-transplantation, none of the signs of SCD recurrence in the transplanted cornea has been observed.

The p.Asn102Ser *UBIAD1* pathogenic variant was found in two families (Ped. nos. 149 and 272) with two and six affected individuals, respectively. There was a great variability in the age of symptoms onset in both families, ranging from 9 y/o (II.6 PatID\#375) to 51 y/o (II.3 PatID\#486). In slit-lamp examination, similar phenotypic features with haze in the central and paracentral parts of the cornea, crystalline formations, and thick yellow-white arcus lipoides in the advanced SCD stages were visible (Fig. [2](#Fig2){ref-type="fig"}m, n). AS-OCT revealed highly reflective deposits localized in the anterior stroma of the central and mid-peripheral part of the cornea (Fig. [2](#Fig2){ref-type="fig"}r). IVCM showed well-demarcated hyperreflective spindle-shaped deposits which created star-like formations in the stromal layer (Fig. [2](#Fig2){ref-type="fig"}o, p). The number of deposits was higher in the advanced stages of SCD and keratocytes could not be visualized.

Discussion {#Sec9}
==========

In this study we have identified p.Thr120Arg, a novel heterozygous point alteration in the *UBIAD1* gene causative of SCD. The second pathogenic variant p.Asp112Asn reported here was previously published by Nickerson et al. \[[@CR14]\] in the context of in vitro functional studies. To the best of our knowledge, no detailed clinical characterization of SCD patients with this pathogenic variant has been provided so far. The current study delivers independent evidence for the pathogenic potential of UBIAD1 p.Asp112Asn and reports the genetic variant for the first time in Polish SCD patients. The third *UBIAD1* pathogenic variant detected in the study, p.Asn102Ser, is identified in the majority of unrelated SCD families in different ethnic groups and it is believed that this variant represents a hot spot change for SCD \[[@CR4]\].

We have identified the pathogenic variant p.Asn102Ser in two unrelated Polish SCD families in as many as 12 out of 18 genetically confirmed SCD patients. One of the families (Ped. no. 272, Fig. [1](#Fig1){ref-type="fig"}d) represents one of the most numerous SCD kindreds, so far reported, for which we have conducted thorough ophthalmological and genetic examinations. Our findings contribute to a previous study describing two other Polish families with SCD as a result of *UBIAD1* p.Asn102Ser \[[@CR11]\] and confirm that the pathogenic variant is also the most common genetic alteration found in SCD patients from Central Europe.

The last decade brought the discovery of several fundamental functions of the *UBIAD1*-encoded protein. These encompass (i) synthesis of human endogenous form of vitamin K~2~ (MK-4) from derivates of a plant form vitamin K~1~ \[[@CR10], [@CR20]--[@CR25]\], (ii) prevention of oxidative damage in tissues by synthesis of non-mitochondrial coenzyme Q10 \[[@CR26], [@CR27]\], and (iii) direct and indirect interaction with proteins that regulate cholesterol synthesis and transport (HMGCR, SOAT1, apoE) \[[@CR10], [@CR28], [@CR29]\]. UBIAD1 protein plays a crucial role in maintaining lipid-cholesterol homeostasis in different cell types \[[@CR10], [@CR12], [@CR21], [@CR30], [@CR31]\] but the molecular mechanism by which UBIAD1 pathogenic variants affect the cornea leading to lipid deposition in SCD patients has yet to be determined.

Defective function of UBIAD1 protein results in reduction of the local synthesis of endogenous form of vitamin K~2~ in cells and impairment of cholesterol and lipid metabolism leading to a continuous steroidogenesis stimulation and tissue-specific cholesterol and lipid deposition \[[@CR10], [@CR29]\]. Codon p.Thr120 of the UBIAD1 protein is placed directly between two other codons which were previously identified to be altered in SCD --- p.Arg119Gly and p.Leu121Phe/Val \[[@CR10]\]. All of these amino acids are placed within the first aspartate--rich motif (FARM) which localizes to the first polypeptide loop of the UBIAD1 protein. It is a highly conserved region that may play a crucial role in synthesis of sterols and isoprenoid lipids, as well as cellular cholesterol binding, storage, and transport \[[@CR10], [@CR12]\]. Accordingly, p.Thr120Arg along with other SCD causing pathogenic variants is predicted to strongly affect UBIAD1 protein folding and stability, protein enzymatic function, and protein--protein interactions. These alterations may have deleterious impact on cholesterol metabolism in the cornea, contributing to lipid deposition and cholesterol esterification, which may lead to corneal haze and crystalline formation, characteristic features of the SCD phenotype.

Some of our SCD patients reported cardiovascular system disorders (6/18; 33%) and/or cholelithiasis (Table [1](#Tab1){ref-type="table"}). The most frequent systemic finding in SCD is an elevated cholesterol level in blood plasma. Generally, hypercholesterolemia is shown to be present in 66% of patients with SCD \[[@CR5]\]. In the 2013--2014 survey on Polish population, the prevalence of hypercholesterolemia averaged 67.3%, (70.3% for men, 64.3% for women) \[[@CR32]\]. Occurrence of cholesterol deposits in the cornea is described to show no relation with severity of systemic dyslipidemia \[[@CR6]\]. Moreover, SCD corneas present a greater tendency to accumulate high-density lipoproteins (HDL) than low-density lipoproteins (LDL) \[[@CR33]\]. Progression of the corneal opacification is also not related to the level of lipids in the blood plasma \[[@CR5]\]. It is shown that statin treatment and control of systemic cholesterol do not inhibit the progression of SCD \[[@CR34]\].

In line with other reports, we have observed a gradual loss of VA in SCD patients which was progressing along with the severity of dystrophic changes and corresponded with the age of affected individuals \[[@CR5], [@CR6], [@CR14], [@CR35]\]. Unlike the moderate severity stage of SCD, which is usually recognized on the basis of slit-lamp biomicroscopy, initial and advanced stages of the disease tend to cause a more significant diagnostic problem. In the early SCD stage, the signs can be easily overlooked and in the advanced stage, fused corneal opacities and stromal deposits may resemble other corneal dystrophies or corneal degeneration. The majority of our patients presented a moderate severity stage of SCD and slit-lamp examination demonstrated a characteristic clinical picture of the dystrophy. Interestingly, at the end of the fifth decade of life in the proband with *UBIAD1* p.Thr120Arg initially mild dystrophic changes progressed rapidly from an early to advanced SCD stage only within a 3-year observation period. It is a quite unusual finding as SCD generally progresses gradually \[[@CR5], [@CR6], [@CR14], [@CR35]\].

In general, the appearance of deposits, their reflectance, location, and the images of corneal epithelium and endothelium in IVCM imaging in our patients is in line with the descriptions by other authors \[[@CR33], [@CR36]--[@CR38]\]. However, in patients with p.Asp112Asn, we also observed small cysts with hyperreflective content in the corneal epithelium (Fig. [2](#Fig2){ref-type="fig"}j); such changes are only rarely observed in SCD patients \[[@CR11], [@CR39]\]. To the best of our knowledge, there are only two other reports on SCD visualized by AS-OCT \[[@CR11], [@CR40]\]. Both studies described stromal hyperreflective opacities limited to the anterior parts of the cornea corresponding with the localization of crystalline formation visible in IVCM images, which is consistent with our observations. In AS-OCT, the appearance of corneal changes was similar in all subjects, but the quantity of deposits was noticeably different and appropriate to SCD stage.

Corneal imaging with IVCM and AS-OCT is proven to be helpful in differential diagnosis of inapparent SCD cases. However, IVCM may not be a conclusive approach as corneal crystalline formations in SCD are similar to those observed, e.g., in cystinosis or infectious crystalline keratopathy. Along with the increasing availability of genetic testing, identification of an *UBIAD1* pathogenic variant has become a necessary complement to ophthalmological examinations as it provides a definitive confirmation of clinical SCD diagnosis.
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